2 Biotech Stocks Set to Go Supernova Soon
Biotech is having a moment right now. Despite the industry's numerous successes in developing treatments for scores of once undruggable indications, investors have backed away from this area of the market this year. The bellwether SPDR S&P Biotech ETF is down by almost 12% year to date.
Investors have avoided this high-growth industry in 2021 for a variety of reasons, including a seemingly stricter Food and Drug Administration, increased scrutiny from the Federal Trade Commission over mergers and acquisitions, key clinical trial failures, and the political blowback over drug prices. These headwinds, however, won't necessarily keep truly promising biotech companies from producing market-crushing gains.
Which biotech stocks have what it takes to overcome these various hurdles? Anavex Life Sciences (NASDAQ: AVXL) and Affimed (NASDAQ: AFMD) are two names that could produce explosive gains for investors in 2022 and beyond. Read on to find out why risk-tolerant investors might want to buy shares of these two biotech stocks soon.
Source Fool.com
